Daniel Loeb
Third Point
Daniel Loeb Strata Critical Medical, Inc stake
total: 588
Third Point SRTA trades
- Total transactions:
- 1
- New positions:
- 1
- Held since:
- 2025 Q3
- Held for:
- 4 quarters
- Latest activity:
- 2025 Q3
According to 2026 Q2 report, Daniel Loeb holds 5,000,000 Strata Critical Medical, Inc (SRTA) shares with a market value of roughly $26.35M accounting for 0.57% of the overall portfolio. To date, the estimated cost basis is nearly $5.06 for "buy" trades. Third Point first purchased SRTA in 2025 Q3, initially acquiring about 5.00M shares.
When did Daniel Loeb buy Strata Critical Medical, Inc (SRTA)?
Daniel Loeb first invested in Strata Critical Medical, Inc (SRTA) in 2025 Q3 at the reported quarter-end price of $5.06 per share.
What's the cost basis of Third Point's SRTA stake?
The estimated cost basis for Strata Critical Medical, Inc (SRTA) stake is around $5.06 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $5.06
Daniel Loeb's historical trades in Strata Critical Medical, Inc
1 result
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q3
|
0.30%
|
5,000,000
|
$5.06
|
$25,300,000
|
new
|
+0.3%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.